Gastrointestinal Tumor Research and Treatment
Open access
Peer reviewed
Scollr summary
What this paper is about
Durable responses were observed in some patients with KIT exon 11 and secondary exon 17/18 mutations, but this exploratory observation does not establish a predictive molecular subgroup and larger prospective studies with systematic molecular, radiological, and safety assessment are warranted.
Full abstract
Read the full abstract
Background: Ripretinib, a switch-control kinase inhibitor approved for advanced gastrointestinal stromal tumor (GIST), inhibits primary and secondary KIT and PDGFRA mutations. Real-world data from Western and Middle Eastern populations remain limited. We report outcomes from a molecularly characterized Israeli multicenter cohort. Methods: We conducted a multicenter retrospective cohort study across seven university-affiliated medical centers in Israel. Patients with advanced GIST receiving Ripretinib at any treatment line were eligible. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and response was assessed according to modified RECIST v1.1. Results: Sixteen patients were identified (median age, 67.5 years; 75.0% received Ripretinib in the fourth-line setting). KIT exon 11 mutations were present in 62.5% of patients, including five with secondary resistance mutations involving exon 13 or exons 17/18. Median PFS was 7.0 months (95% CI, 2.0–13.0) and median OS was 14.7 months (95% CI, 4.4–NR). Individual outcomes varied substantially, with PFS ranging from 2.0 to 60.2 months and OS from 2.2 to 60.2 months. Three patients achieved complete responses, with PFS of 20.0, 33.6, and 60.2 months. ORR was 56.3% (CR, n = 3; PR, n = 6) and DCR was 81.3%. No dose reductions or treatment discontinuations due to adverse events were documented; however, adverse events were recorded in only 4 of 16 patients. Conclusions: Ripretinib demonstrated clinical activity in this small, heavily pre-treated cohort. The relatively high ORR and wide variability in outcomes should be interpreted cautiously given the small sample size, retrospective design, and absence of central radiological review. Durable responses were observed in some patients with KIT exon 11 and secondary exon 17/18 mutations, but this exploratory observation does not establish a predictive molecular subgroup. Larger prospective studies with systematic molecular, radiological, and safety assessment are warranted.
Direct answer
What can I do from this paper page?
Use this page to scan "From Rapid Progression to Long-Lasting Complete Response: A Wide Range of Ripretinib Activity for Metastatic GIST—A Real-World Cohort" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Gastrointestinal Tumor Research and Treatment, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{Edri2026From,
title = {From Rapid Progression to Long-Lasting Complete Response: A Wide Range of Ripretinib Activity for Metastatic GIST—A Real-World Cohort},
author = {Hanna T. Frumin Edri and Walid Shalata and Ilia Berezhnov and Tanzila Tairov and Tatiana Bobrovitsky and Dan Mirelman and Esther Tahover and Ofer Purim and Yuval Dadon and Katerina Shulman and Gali Perl and Gil Bar Sela and Maria Passhak and Ronen Brenner},
journal = {Medical Sciences},
year = {2026},
doi = {10.3390/medsci14050549},
url = {https://doi.org/10.3390/medsci14050549}
}FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new Gastrointestinal Tumor Research and Treatment papers?
Follow Gastrointestinal Tumor Research and Treatment in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for From Rapid Progression to Long-Lasting Complete Response: A Wide Range of Ripretinib Activity for Metastatic GIST—A Real-World Cohort. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app